The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 18.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
Aptorum Group Ltd APM
Clears the common standardAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
read at $0.70
Aptorum Group Ltd holds its Markup at $0.70.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · screen not yet scored
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 9 days |
| Price | $0.70 |
| Valuation | N/A trailing · -0.99 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.17 |
The business, in plain words · what the numbers mean
| Forward P/E | -1.0x |
| Profit margin | 0.0% currently unprofitable |
| Return on equity | -10.8% not currently earning a positive return on equity |
| Debt to equity | 0.25 minimal debt — a conservative balance sheet |
| Current ratio | 0.78 below 1 — short-term bills exceed liquid assets |
| Beta | 0.17 barely tracks the market's swings |
| Market cap | $2M |
| Employees | 1 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to United Kingdom and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in APM's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.83 | +7.0% | · | $1,070 | +7.0% |
| 2 months | $0.91 | -2.8% | · | $973 | -2.8% |
| 3 months | $0.80 | +10.6% | · | $1,106 | +10.6% |
| 6 months | $1.33 | -33.5% | · | $665 | -33.5% |
| 1 year | $1.07 | -17.3% | · | $827 | -17.3% |
| 2 years | $4.50 | -80.3% | · | $197 | -80.3% |
| 3 years | $2.99 | -70.4% | · | $296 | -70.4% |
| 5 years | $29.00 | -97.0% | · | $31 | -97.0% |
Historical returns from market close data. Past performance does not guarantee future results.